Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators

Shujing Xu; Lin Sun; Waleed A. Zalloum; Tianguang Huang; Xujie Zhang; Dang Ding; Xiaoyu Shao; Xiangyi Jiang; Fabao Zhao; Simon Cocklin; De Clercq Erik; Christophe Pannecouque; Alexej Dick; Xinyong Liu; Peng Zhan

doi:10.3390/molecules27238415

Abstract

1 min read

HIV-1 capsid (CA) performs multiple roles in the viral life cycle and is a promising target for antiviral development. In this work, we describe the design, synthesis, assessment of antiviral activity, and mechanistic investigation of 20 piperazinone phenylalanine derivatives with a terminal indole or benzene ring. Among them, F2-7f exhibited moderate anti-HIV-1 activity with an EC50 value of 5.89 μM, which was slightly weaker than the lead compound PF74 (EC50 = 0.75 μM). Interestingly, several compounds showed a preference for HIV-2 inhibitory activity, represented by 7f with an HIV-2 EC50 value of 4.52 μM and nearly 5-fold increased potency over anti-HIV-1 (EC50 = 21.81 μM), equivalent to PF74 (EC50 = 4.16 μM). Furthermore, F2-7f preferred to bind to the CA hexamer rather than to the monomer, similar to PF74, according to surface plasmon resonance results. Molecular dynamics simulation indicated that F2-7f and PF74 bound at the same site. Additionally, we computationally analyzed the ADMET properties for 7f and F2-7f. Based on this analysis, 7f and F2-7f were predicted to have improved drug-like properties and metabolic stability over PF74, and no toxicities were predicted based on the chemotype of 7f and F2-7f. Finally, the experimental metabolic stability results of F2-7f in human liver microsomes and human plasma moderately correlated with our computational prediction. Our findings show that F2-7f is a promising small molecule targeting the HIV-1 CA protein with considerable development potential.

Related publications

Article2023

Design, synthesis, and mechanistic study of 2-piperazineone-bearing peptidomimetics as novel HIV capsid modulators

Xujie Zhang, Lin Sun, Shujing Xu, Tianguang Huang, Fabao Zhao, Dang Ding, Chuanfeng Liu, Xiangyi Jiang, Yucen Tao, Dongwei Kang, De Clercq Erik, Christophe Pannecouque, Simon Cocklin, Alexej Dick, Xinyong Liu, Peng Zhan

Article2024

Discovery of low‐molecular‐weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability

Xiangyi Jiang, Zhen Gao, Prem P. Sharma, Sumit Kumar, Brijesh Rathi, Xiangkai Ji, Jiaojiao Dai, Minghui Xie, Guanyu Dong, Shujing Xu, De Clercq Erik, Christophe Pannecouque, Alexej Dick, Peng Zhan, Xinyong Liu

Article2022

Design, Synthesis, and Mechanistic Study of 2-Pyridone-Bearing Phenylalanine Derivatives as Novel HIV Capsid Modulators

Xujie Zhang, Lin Sun, Shujing Xu, Xiaoyu Shao, Ziyi Li, Dang Ding, Xiangyi Jiang, Shujie Zhao, Simon Cocklin, De Clercq Erik, Christophe Pannecouque, Alexej Dick, Xinyong Liu, Peng Zhan

Article2020

Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities

Lin Sun, Alexej Dick, Megan E. Meuser, Tianguang Huang, Waleed A. Zalloum, Chin‐Ho Chen, Srinivasulu Cherukupalli, Shujing Xu, Xiao Ding, Ping Gao, Dongwei Kang, De Clercq Erik, Christophe Pannecouque, Simon Cocklin, Kuo‐Hsiung Lee, Xinyong Liu, Peng Zhan

Article2023

Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators

Shujing Xu, Lin Sun, Michael J. Barnett, Xujie Zhang, Dang Ding, Anushka Gattu, Dazhou Shi, Jamie R. H. Taka, Wenli Shen, Xiangyi Jiang, Simon Cocklin, De Clercq Erik, Christophe Pannecouque, David C. Goldstone, Xinyong Liu, Alexej Dick, Peng Zhan